Dr. Jack West reviews the key differences between findings that are worthy of clinical research and those that should be broadly adopted as a standard of care in cancer treatment, and differences in practice in academic vs. community practice. (10:03)
Dr. Jack West reviews evidence that a subset of patients with advanced NSCLC demonstrate “hyper-progressing disease” (HPD), worsening cancer at a faster rate, on immune checkpoint inhibitor therapy, more commonly than seen in patients on chemotherapy. (7:22)
Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab. (9:08)